Why Moderna Stock Was Down 31.8% in Q1 as the S&P 500 Had Its Worst Quarter Since 2022
The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the year.The vaccine maker's sales continue to struggle years after its top line exploded during the COVID-19 pandemic. More recently, the conspicuous exit of a top Food and Drug Administration (FDA) official has darkened investor sentiment.The company's revenues have cratered now that the coronavirus pandemic no longer rages. Moderna's 2022 sales of $19.3 billion seem like a distant memory. The company delivered just $3.2 billion in 2024, as its year-end and Q4 earnings released in early January showed a more than 50% decline year over year. Results across the board disappointed investors by failing to meet expectations. Continue reading
The first quarter of 2025 was a tough one. The S&P 500 lost 4.6%, and the Nasdaq Composite lost 10.4%. Following the trend, shares of Moderna (NASDAQ: MRNA) slid 31.8% in the first three months of the year.
The vaccine maker's sales continue to struggle years after its top line exploded during the COVID-19 pandemic. More recently, the conspicuous exit of a top Food and Drug Administration (FDA) official has darkened investor sentiment.
The company's revenues have cratered now that the coronavirus pandemic no longer rages. Moderna's 2022 sales of $19.3 billion seem like a distant memory. The company delivered just $3.2 billion in 2024, as its year-end and Q4 earnings released in early January showed a more than 50% decline year over year. Results across the board disappointed investors by failing to meet expectations.
